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Abstract 
LKB1 Deficient Non-small Cell Lung Cancer Cells are Vulnerable to Energy 
Stress Induced by ATP Depletion 
Chao Yang 
Advisory Professor: John V. Heymach, M.D., Ph.D. 
Lung cancer is the second most frequent cancer in United States, which 
represents about 13.5% of new cancer cases every year. It accounts for about 
27.2% of all cancer related deaths, which is more than the sum of deaths 
caused by prancretic, breast and colorectal. On average, only about 16% of 
lung cancer patients survive beyond 5 years. LKB1 is the third most mutated 
gene in lung cancer. It has been shown that LKB1 is mutated in at least 15% to 
30% of NSCLC. Tumor with LKB1 mutation is associated with poor 
differentiation, high metastasis and worse response to chemotherapy. The 
development of targeted therapies has greatly improved the prognosis of a 
small subtype of lung cancer. However, there is no targeted therapy for this 
subtype and less effective chemotherapy is still being used as the first line 
treatment.  
In normal cells, LKB1 regulates cellular energy by balancing energy production 
and consumption. Because tumor cells need vast amounts of energy for their 
growth, they must adapt alternative strategies to amplify their energy production. 
During low energy condition in normal cells, LKB1 signals cellular proteins to 
decrease energy consumption, often resulting in decreased cell growth. 
However, in LKB1 deficient tumor cells, there is no signal to slow down cell 
growth. As such, these tumor cells have a disrupted balance between energy 
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consumption and production, and LKB1 deficient tumor cells are able to escape 
the normal growth inhibitory signals, resulting in unrestricted cell growth. I 
hypothesize that targeting cellular pathways regulating energy production in 
LKB1 deficient NSCLC will inhibit the growth of these tumor cells. 8-
chloroadenosine (8-Cl-Ado) is a compound which depletes cellular ATP.  In this 
study, we have identified that 8-Cl-Ado is a potential therapeutic agent for 
targeting tumors with LKB1 deficiency. To determine the role of LKB1 and 8-Cl-
Ado in cellular metabolism, we generated isogenic cell lines with either LKB1 
stable re-constitution or knockdown. Cells with LKB1 re-constitution showed 
decreased sensitivity to 8-Cl-Ado. Similarly, cells with LKB1 stable knockdown 
displayed increased sensitivity to 8-Cl-Ado. Additionally, analysis on cellular 
ATP and reactive oxygen species (ROS) levels showed that 8-Cl-Ado caused a 
greater reduction in ATP and increase in ROS in LKB1 deficient cells compared 
to cells with wild-type LKB1. Furthermore, a metabolic study demonstrated that 
LKB1 deficiency is associated with reduction in mitochondrial membrane 
potential. It also results in a phenotype with increased anaerobic respiration but 
decreased oxidative phosphorylation. These findings indicate that LKB1 can 
regulate the balance between anaerobic and aerobic respiration. This shifts 
cells toward a less efficient energy production mechanism, rendering a potential 
vulnerability of LKB1 deficient NSCLC to metabolic disruption. 
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1.1 Overview  
Lung cancer is the second most frequent cancer in United States, which 
represents about 13.5% of new cancer cases every year (1). It is also the 
leading cause of cancer related death in the U.S., which accounts for about 
27.2% of all cancer related deaths (1). In 2014, it is estimated that 220,000 
people will be diagnosed with this disease and more than 159,000 people will 
die from it (2). On average, only about 16% of lung cancer patients survive 
beyond 5 years (1). The development of targeted therapies has greatly 
improved the prognosis of a small subtype of lung cancer. However, for most 
patients, less effective chemotherapy is still being used as the first line 
treatment. Therefore, there is an urgent need to better understand the 
molecular biology of lung cancer and develop more effective treatment 
strategies.    
 
1.2 Non-small cell lung cancer 
Lung cancer is classified into two major groups: small cell lung cancer (SCLC) 
and non-small cell lung cancer (NSCLC). NSCLC accounts for about 85% to 90% 
of lung cancers. It is furthered grouped into adenocarcinoma (AD), squamous 
cell carcinoma (SQ), and large cell carcinoma (LC) (3).   
Various genetic alternations have been discovered in NSCLC, and these dictate 
the heterogeneity of lung cancer and the difficulties for treatment. Among all the 
mutated genes in lung cancer, TP53, KRAS, LKB1, EGFR, KEAP1 and NFE2L2 
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are the most frequently mutated (4). Detailed subtype studies have revealed 
some distinct patterns between subtypes and genetic alteration (4). For 
instance, MYCN amplifications often happen in squamous cell carcinoma; 
KRAS, EGFR, and LKB1 mutations mainly occur in adenocarcinoma (4). Due to 
these differences in mutations, the weakness of general chemotherapy as the 
first line of treatment is apparent.  
 
1.3 LKB1 in lung cancer 
LKB1 is a serine/threonine protein kinase that functions as a tumor suppressor. 
It was first identified in Peutz-Jeghers syndrome (PJS), which is characterized 
by the development of hamartomatous polyps in the gastrointerstinal tract and 
melanin pigmentation on the lips (5-7). PJS patients with germ-line LKB1 
mutation are associated with increased risk for developing cancer at multiple 
sites (8). When compared to the cancer risk for general population by the age of 
60, the risk of PSJ patients carrying an LKB1 mutation is elevated by eight-fold 
(9).   
The human LKB1 gene is located on the short arm of chromosome 19  (10,11) . 
This region is one of the most frequently altered regions in lung 
adenocarcinomas (11,12). Adenocarcinoma is one of the most abundant 
subtypes of lung cancer and accounts for about 40% of lung cancer cases 
worldwide (3). Recent studies have shown that LKB1 is mutated in at least 15 to 
30% of NSCLC (11,13-16). LKB1 mutations commonly overlap with activating 
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KRAS mutation, accounting for about 7%-10% of all NSCLC (17,18). These two 
mutations result in a very aggressive phenotype. Mouse model studies have 
shown that mice with KrasG12D and LKB1 deletion in lung have dramatically 
increased tumor burden and metastasis (14,19).  It has also been demonstrated 
that LKB1/KRAS mutant tumors have a worse response to chemotherapy 
compared to tumors with KRAS mutations alone (20).  
 
1.4 LKB1 signaling 
LKB1 is a master kinase that phosphorylates and activates 14 other kinases 
(21,22).  LKB1 was first discovered to play a role in regulating G1 cell cycle 
arrest as demonstrated by ectopic expression of LKB1 in HeLa and G361 cells, 
which do not normally express LKB1 (23). Transgenic mouse studies have 
demonstrated a role for LKB1 in early development by showing that LKB1 
knockout is associated with embryonic lethality (24-26). LKB1 functions in a 
complex with two other proteins, MO25 and STRAD (27,28). Several studies 
have suggested that binding to MO25 and STRAD could re-localize LKB1 from 
the nucleus into the cytoplasm and thereby enhance its catalytic activity  
(27,29) . 
The AMP-activated protein kinase (AMPK) is the best characterized substrate 
of LKB1 (30-33). AMPK is known for its function in regulating cellular energy 
metabolism (34). In response to an increasing AMP/ATP ratio, LKB1, when 
bound to MO25 and STRAD, has been shown to phosphorylate AMPK at 
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Thr172. Subsequently, phosphorylated AMPK regulates the activity of multiple 
downstream signaling pathways to restore ATP levels in the cell.  
Research has shown a conserved role of LKB1 in regulating cell polarity  
(35,36). LKB1-AMPK modulates the phosphorylation of myosin regulatory light 
chain and microtubule-associated proteins, which is important for the 
establishment and maintenance of cell polarity (37,38). LKB1 loss is also 
associated with epithelial-mesenchymal transition (EMT) (39). Given the role of 
cell polarity in the maintenance of EMT (40), it suggests that disrupted cell 
polarity due to LKB1 loss may contribute to the increased migration and 
invasive characters of lung cancer cells.  
Mammalian target of rapamycin (mTOR) is known for its role in regulating cell 
growth and proliferation. Its downstream proteins are involved in variety of 
cellular processes, such as cell cycle, protein synthesis and autophagy  (41). 
Under energy stress, LKB1 phosphorylates AMPK which modulates the 
Tuberous sclerosis proteins 1 and 2 (TSC1-TSC2) complex through direct 
phosphorylation on TSC2 T1227 and S1345. The phosphorylated complex then 
inhibits the mTOR signaling by inactivating Rheb (42). This inhibition of mTOR 
stalls cell growth and proliferation to conserve energy, thus protects cells from 
this unfavorable condition.  
Prostate cancer studies have shown that AMPK activation offers a survival 
advantage to prostate cancer cells during energy stress and AMPK inhibition 
could lead to increasing in apoptosis (43). Furthermore, it has been shown that 
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AMPK phosphorylation at Thr-172 was nearly completely lost in embryonic 
fibroblasts lacking LKB1 expression (33). Those fibroblasts were also sensitive 
to apoptosis induced by energy stress (33). Given the role of AMPK in 
regulating the energy metabolism, these findings suggest that LKB1 deficient 
lung cancer may be associated with altered energy metabolism and sensitivity 
to metabolic interruption. 
 
1.5 Metabolism and cancer  
Cell metabolism refers to a series of chemical reactions that converts nutrients 
to energy and building blocks (proteins, nucleic acid, and lipids) for cell growth 
and proliferation. Adenosine triphosphate (ATP) is the principal energy supplier 
for energy-dependent biological processes, however the cycle of cellular 
metabolism relies on the compound nicotinamide adenine dinucleotide 
phosphate (NADPH). ATP can be produced through both glycolysis and 
oxidative phosphorylation. Glycolysis, as shown in Figure 1.1,  is comprised of a 
ten step reaction that takes place in the cytoplasm by metabolizing glucose to 
pyruvate.  These reactions yield two molecules of ATP, two molecules of 
pyruvate and two electron carrying molecules of NADH per molecule of glucose. 
The pyruvate can further be converted to acetyl-coA, which will enter the 
mitochondria to generate citrate. Citrate will then pass through the TCA cycle to 
generate electron carriers for the electron transport chain. During oxidative 
phosphorylation, the electrons from the carriers produced by TCA cycle will be 
donated and passed though mitochondrial complexes to generate a proton 
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gradient. Finally, the protons will flux back into the mitochondria through ATP 
synthase, which converts ADP to ATP. Overall, oxidative phosphorylation 
generates 38 molecules of ATP per molecule of glucose (44).  
Warburg first proposed that cancer cells display enhanced aerobic glycolysis in 
the presence of high oxygen tension (45). Compared to oxidative 
phosphorylation, glycolysis is a rapid but less efficient way of producing energy. 
In order to support the rapid growth of cell division, tumor cells have to keep an 
abnormally high rate of glycolysis. This transformation consumes a huge 
amount of glucose, but also provides a biosynthetic advantage for tumor cells. 
The increased glucose flux allows for effective diversion of carbon for the 
increased energy, biosynthesis and redox needs (46).  
The fast growing tumor requires a sustained supply of nutrients and oxygen. 
However, the lagging growth of new blood vessels decreases nutrients and 
results in hypoxic stress (47-49). In this regard, high glycolysis permits tumor 
cells to live under low oxygen tension. Also, the production of lactate by 
glycolysis creates an acidic microenvironment, which facilitates tumor invasion 
and suppresses immune effectors (50-52)  .  
The pentose phosphate pathway (PPP) is the main source of NADPH synthesis.  
This pathway uses the intermediate products of glycolysis to generate NADPH  
(53). NADPH is a critical substrate for fatty acid synthesis. It is also a major 
antioxidant agent to protect cells from the harsh tumor microenvironment and 
chemotherapy (53).  
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Figure 1.1 Illustration of cell metabolism. 
Glucose is taken up by cells and converted to pyruvate. In normal cells, 
pyruvate will be converted to acetyl-coA to undergo oxidative 
phosphorylation (OXPHOS), through TCA cycle. Glucose-6-phosphate can 
also be taken up by pentose phosphate pathway (PPP) to produce NADPH. 
Citrate from TCA cycle can be converted back to Acetyl-CoA and undergoes 
fatty acid synthesis. Under energy stress, fatty acid oxidation breaks down 
lipids to acetyl-CoA and produce FADH2 and NADH to fuel TCA cycle and 
OXPHOS. Citrate can also be converted to isocitrate and α-ketogluatarate to 
restore NADPH level. In cancer cells, pyruvate is preferentially converted to 
lactate in cytoplasm. 
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Reactive oxygen species (ROS) refers to a diverse class of radical species that 
are byproducts of oxidative phosphorylation. The majority of ROS generation 
takes place in the mitochondria, as shown in Figure 1.2. Excess electrons at 
mitochondrial complex I and complex III will directly pass to oxygen and 
generate superoxide anions (54,55). The superoxide anions will then be 
dismutated into hydrogen peroxide by superoxide dismutase.  
 Low levels of ROS are thought to promote tumorigenesis by modulating kinase 
and phosphatase activities (56-58). At moderate levels, ROS stabilizes HIF-1, 
which in turn regulates the transcription of genes that control metabolic 
reprograming, such as GLUT1 (glucose transporter), PKM2 (increase glucose 
shunting to PPP), and PDK1 (prevents pyruvate to be used by mitochondrial 
respiration) (59-61). At high levels, however, ROS damages the cellular 
membrane and macromolecules, triggering senescence and causing apoptosis 
(62-65). 
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Figure 1.2 The production of ROS in mitochondria. 
The NADH and FADH2 generated by TCA cycle will denote electrons to 
electron transport chain to reduce oxygen to water and produce ATP at 
complex V. However, electron leaked from complex I and III will generate 
superoxide (O2.-). Then, superoxide will be dismutated to hydrogen peroxide 
(H2O2) by superoxide dismutases (SOD1 in the intermembrane space and 
SOD2 in the matrix). Reprinted from Journal of Hematology & Oncology 
(permission is not required by journal) 2013, 6:19  doi:10.1186/1756-8722-6-
19  (66).  
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1.6 LKB1-AMPK in cell metabolism 
LKB1 modulates cell metabolism by mediating the activation of AMPK. AMPK is 
the master sensor of cellular energy status and has a crucial role in the 
response to metabolic stress. Tissue specific LKB1 knockout mouse models 
have shown that LKB1 is the principal upstream kinase that activates AMPK  
(67). As mentioned above, AMPK inhibits mTOR signaling by phosphorylating 
TSC complex in response to energy stress. In addition to the role of mTOR in 
regulating protein translation by 4EBP1 and S6K1, mTOR also modulates the 
translation of Hypoxia-inducible factor 1-alpha (HIF1-α) and MYC (68). HIF1-α 
is a master regulator of cellular response to oxygen fluctuation (69).  In normal 
cells, the HIF1-α protein is degraded by unbiquitination under normoxic 
condition but stabilized under hypoxic condition (70). In tumor cells, however, 
HIF1-α is activated by oncogenic signaling, amplifying the transcription of 
various glycolytic enzymes, promoting the cell to carry out glycolysis.  In 
addition, MYC collaborates with HIF1-α in terms of enhancing glycolysis. It also 
activates the transcription of genes that involve in the mitochondrial biogenesis 
(71,72) . 
The LKB1-AMPK signaling pathway has also been shown to modulate other 
key metabolic signaling pathways other than mTOR signaling. AMPK inhibits 
acetyl-CoA carboxylase (ACC) by phosphorylation (73). ACC is the major 
enzyme in fatty acid synthesis. Fatty acid is an important energy source in 
addition to glucose and glutamine. The synthesis is an anabolic process that 
requires acetyl-CoA and NADPH. Its oxidation however is a catabolic process 
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that generates NADPH and acetyl-CoA for the electron transport chain and TCA 
cycle to generate ATP. Under energy stress, activation of AMPK by LKB1 
inhibits fatty acid synthesis through ACC phosphorylation, and in turn stalls 
energy consumption and promotes its production (74).  
As mentioned previously, NADPH is a key product of the pentose phosphate 
pathway. It plays a role as cofactor and reduces many enzymatic reactions that 
are important to macromolecular biosynthesis. In addition, NADPH is a crucial 
anti-oxidant, which reduces both glutathione (GSH) and thioredoxin (TRX) to 
scavenge ROS (75). It has been shown that LKB1 decreases ROS levels by 
promoting the NADPH production through fatty acid synthesis (74). 
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Figure 1.3 AMPK-regulated proteins mediate cell metabolism.  The left panel 
shows the anabolic processes that consume ATP. Whereas, the right panel 
demonstrates the catabolic processes. Under energy stress, increased AMP 
promotes AMPK phosphorylation by LKB1. Subsequently, AMPK will 
suppress the ATP consuming processes and promote ATP production 
processes.  
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1.7 8-Chloroadenosine (8-Cl-Ado) 
8-Cl-Ado is a RNA-directed nucleoside analogue that has been investigated 
under a phase I clinical trial for the treatment of chronic lymphocytic leukemia 
(CLL) (76). Preclinical studies have shown that 8-Cl-Ado could target various 
cancer cell lines, such as primary CLL cells, glioma, myeloid leukemia, colon 
and lung (76-82). The cytotoxicity of 8-Cl-Ado depends on its phosphorylation to 
8-Cl-ADP and 8-Cl-ATP by adenosine kinase (83).  The increased 8-Cl-ATP 
inhibits mRNA transcript synthesis by incorporating into the RNA as a chain 
terminator or by inhibiting polyadenylation (84,85). In addition, 8-Cl-ADP may 
compete with ADP for binding to the active site of ATP synthase to inhibit ATP 
production (84,86). 
 
1.8 Seahorse assay 
The seahorse assay (Seahorse Bioscience) provides a comprehensive method 
to assess two key parameters of cellular metabolism: oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR). Oxygen molecules are used 
at the final step of the electron transport chain to accept electrons and protons 
to form water. Its consumption is proportional to mitochondrial respiration. 
Therefore, the OCR is used as an indicator of mitochondrial respiration. As 
mentioned previously, glucose is metabolized to pyruvate, which is then 
converted to lactate during glycolysis. The production of lactate releases proton 
into the extracellular medium, which then acidifies the medium surrounding the 
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cells. The extracellular acidification rate is therefore used as an indicator of 
glycolysis.  
 
1.9 Mitochondrial stress test 
This assay studies the function of the mitochondria by assessing its response to 
various parameters. The cells are metabolically perturbed by sequentially 
adding four different compounds. The first injected compound is Oligomycin, 
which is a known inhibitor of ATP synthase (Complex V). Upon adding it to the 
medium, it blocks the proton channel of ATP synthase, thus causing a decrease 
in oxygen consumption. It is used to evaluate the percentage of oxygen 
consumption that is devoted to ATP synthase. The second compound is FCCP 
(carbonilcyanide p-triflouromethoxyphenylhydrazone), which depolarizes the 
mitochondrial membrane potential by transporting protons across the 
mitochondrial membrane rather than ATP synthase. The collapse of the 
mitochondria membrane potential causes a rapid increase in energy and 
oxygen consumption, but with no ATP production.  Overall, FCCP treatment is 
used to measure the maximum respiration and determine the spare respiratory 
capacity of cells. The third and fourth compounds are Rotenone and Antimycin 
A, both of which are injected into cells together. Rotenone is a complex I 
inhibitor, which prevents the electron transport.  Antimycin A is a complex III 
inhibitor, which stalls the generation of proton gradient. These two compounds 
can shut down mitochondrial respiration, causing a decrease in oxygen 
consumption. They are used to calculate the non-mitochondrial respiration (87).   
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1.10 Glycolysis stress test 
Similar to the mitochondria stress test, the glycolysis stress test studies the 
glycolytic potential of cells by exposing them to chemical insults. Initially, the 
ECAR of cells are measured in the medium without glucose. Glucose is then 
injected into the cell medium, which will be taken up and metabolized to lactate. 
The product of lactate leads to the acidification of medium surrounding the cells, 
and in turn it causes a rapid increase in ECAR. The difference of ECAR with 
and without glucose is the rate of glycolysis under basal condition. The second 
injection is Oligomycin, as mentioned previously, this shifts the energy 
production to glycolysis by inhibiting ATP synthase. Subsequently, Oligomycin 
causes a sharp increase in ECAR, which is the maximum glycolytic capacity of 
the cells. The final injection is 2-DG, which prevents glucose from being 
catabolized by glucose hexokinase which results in a subsequent sharp 
reduction in ECAR. This decrease in ECAR confirms that the ECAR produced 
in experiment is due to glycolysis (88). 
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2.1 Cell Culture and viral infection 
All cells were cultured in RPMI-1640 media (Sigma) supplemented with 10% 
fetal bovine serum, and 1% penicillin-streptomycin.  pLenti-GIII empty vector or 
construct expressing wild type LKB1 (LV323938, Applied Biological Materials 
Inc) was used for  expressing LKB1 in A549 and H460 cells. Two independent 
shRNAs (V3LHS_348649 and V3LHS_639000) and scramble control vectors 
were purchased from Open Biosystems for stably knocking down LKB1. 
Vectors were transiently transfected with 2nd Generation Packaging System 
(psPAX2 and pMD2.G) into 293T cells by using Lipofectamine 2000 and Plus 
reagents (Life Technologies). Viral supernatant was collected 3 days after 
transfection and mixed with PEG-it Virus Precipitation Solution (LV810A-1, 
System Biosciences) overnight at 4°C. Virus pellets were then collected and re-
suspended in HBSS solution containing HEPES. NSCLC cells were infected 
and incubated with the viral particles supplemented with polybrene (AL-118, 
Sigma) overnight in the CO2 incubator at 37°C. Infected cells were selected by 
2 μg/mL puromycin.   
 
2.2 Cell Proliferation Assay 
Cells were seeded in 96 well plates at 2,000 cells per well. Various doses of 8-
Cl-Ado were added to each well on second day after plating. The effect of each 
dose of 8-Cl-Ado was measured in triplicate. Sevety-two hours later, 10 μl/well 
of CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was added to the 
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treated cells. The plates were read using the FLUOstar Optima luminescence 
reader (BMG Labtech). IC50 values were calculated by Calcusyn (Biosoft). 
  
2.3 Western blot and anti-bodies 
Protein lysates were collected by lysing cells with cell lysis buffer (1% Triton X-
100, 50mM HEPES, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 
10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol, and freshly added 
protease and phosphatase inhibitors from Roche Applied Science 
#04693116001 and 049006845001, respectively. pH was adjusted to 7.4. The 
protein concentration was determined by DC Protein Assay kit (Bio-Rad). 30 μg 
of protein was mixed with 5x sample buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% 
glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue), and boiled at 95°C 
for 5 minutes. Samples were resolved on polyacrylamide gel (Criterion™ 
TGX™, Bio-Rad) and transferred to nitrocellulose membrane.  Membranes 
were blocked with 5% milk at room temperature for 1 hour, and then incubated 
overnight at 4°C with primary antibodies: LKB1(#3050, Cell Signaling), pACC 
Ser79 (#11818, Cell Signaling), pAMPK Thr172 (#4188, Cell Signaling), NRF2 
(2178-1, Epitomics), and p-p70S6K Thr389 (#9205, Cell Signaling). 
Immunodetection was performed using Goat anti-Rabbit IgG(H+L)-HRP 
conjugated secondary antibody (Bio-Rad, #170-6515) and SuperSignal West 
Pico Chemiluminescent Substrate(Thermo Scientific,#34080). 
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2.4 Seahorse analysis 
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
was measured by a Seahorse Bioscience XF96 extracellular flux analyzer. The 
Mito Stress test kit and Glycolysis Stress test kit were purchased from 
Seahorse Biosciences. Briefly, cells were plated at 15,000 cells/well the night 
before the experiment. The following day, the cells were washed 3 times with 
XF Assay Medium (#102365-100) and incubated in a CO2 free incubator for 1 
hour. Following incubation, the plates and Cartridges loaded with test 
compounds were loaded into the analyzer and analyzed according to 
manufacturer’s protocol (Seahorse Bioscience).   
 
2.5 ROS measurement 
ROS was measured by using either DCFDA or CellRox DeepRed (C10422, Life 
Technologies). Briefly, the cells were plated into 6-well plates at 100,000 
cells/well. On following day, 8-Cl-Ado (5µM) was added into medium. After 48 
hours, the cells were washed with PBS once and incubated in fresh medium 
containing probe (DCFDA: 20µM, DeepRed 2.5µM) for 30 mins. The cells were 
then trypsinized into a single cell suspension and washed with PBS again, 
suspended in medium and analyzed by FACS. 
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2.6 ATP measurement 
Luminescence based measurement: cells were initially plated into a 384-well 
plate at 1,000 cells/well. The following day, 8-Cl-Ado was added into cell 
medium. After 6 h, cells were processed according to the manufacture’s 
protocol (ATPlite, PerkinElmer). All the plates were screened by the BMG 
reader for luminescence signal.  
LC-MS based ATP measurement was carried out according to the procedure 
outlined before (86).  
 
2.7 Mitochondrial function  
The mitochondrial mass and potential were measured by MitoTracker Deep 
Red FM (M22426, Life Technologies) and MitoTracker Orange CMTMRos 
(M7510, Life Technologies) respectively. Briefly, the cells were plated into 6-
well plates at 200,000 cells/well. The following day, the cells were washed with 
PBS once and incubated in fresh medium containing 25nM MitroTracker probe 
for 30 minutes. The cells were then trypsinized into a single cell suspension and 
washed with PBS again. Finally, the cells were suspended in medium and 
analyzed by FACS. 
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2.8 Statistical analysis 
Unless indicated in the figure legends, all the statistical analysis was done by 
using GraphPad Prism 6 (GraphPad Software, Inc). Results are reported as 
mean ± SE. Statistical significance was calculated by a two-sided student t test 
or one-way ANOVA and determined to be significant as p < 0.05.  
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CHAPTER 3: RESULTS 
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3.1 8-Cl-Ado selectively targets LKB1 deficient NSCLC cells 
A panel of NSCLC cell lines was initially screened with various commonly used 
chemotherapy agents to study the correlation between LKB1 status and drug 
sensitivity (in collaboration with Dr. John Minna at UTSW). The results were 
consistent with reported mouse studies which showed that KRAS driven mice 
with LKB1 conditional knockout in lung had a worse response rate to 
chemotherapy  (20). As shown in Figure 3.1 (A) and (B), LKB1 deficient cells 
did not show any significant increase in the sensitivity to either chemotherapies 
or their combinations which have been commonly used in the clinic for the 
treatment of lung cancer. However, cells with LKB1 deficiency showed a 
selective vulnerability to 8-Choloradenosine (8-Cl-Ado). Further, we correlated 
the sensitivity to 8-Cl-Ado of NSCLC cell lines with their LKB1 protein 
expression determined by RPPA. As shown in Figure 3.1 (C), each cell line’s 
LKB1 protein level was correlated to its IC50 value to 8-Cl-Ado. On average, cell 
lines with high LKB1 protein levels were associated with higher IC50 values than 
those with low LKB1 protein levels. The result confirms the finding that LKB1 
deficient cells are selectively vulnerable to 8-Cl-Ado. Overall, these findings 
suggest that LKB1 plays a significant role in regulating the response to 8-Cl-
Ado in NSCLC cells. 
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Figure 3.1 NSCLC cells with LKB1 deficiency are associated with increased 
sensitivity to 8-Cl-Ao. (A) Response of LKB1 deficient cells to standard agents 
used for NSCLC treatment in clinic. Cells were grouped according to their 
LKB1 status (in collaboration with Dr. John Minna at UTSW). The fold change 
refers to the percentage difference of average IC50 between LKB1 deficient 
and LKB1 wild type groups. The P value was determined by Wilcox test. The 
significant difference was marked with asterisk sign. 
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Figure  3.1  NSCLC cells with LKB1 deficiency are associated with 
increased sensitivity to 8-Cl-Ao (in collaboration with Dr. John Minna at 
UTSW).  (B) Comparison of average IC50 (Log10) according to LKB1 status 
(**p=0.0005). (C) Comparison of average IC50 (Log10) between cells with low 
LKB1 and high LKB1 protein expression (**p=0.007). Cells with LKB1 protein 
level lower than the median value are considered LKB1 low, and vice versa. 
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Cell Line KRAS Status 
LKB1 
Status 
IC50 to 8-
Cl-Ado 
(µM) 
Cell 
Line 
KRAS 
Status 
LKB1 
Status 
IC50 to 8-
Cl-Ado 
(µM) 
H441 Mutated WT 0.47 HCC95 WT WT 0.17 
HCC2279 WT WT 1.55 H1155 Mutated WT 0.47 
Calu-3 WT WT 1.58 H1648 WT WT 0.56 
HCC1171 Mutated WT 1.58 H2347 Mutated WT 0.74 
SK-LU-1 Mutated WT 1.66 H358 Mutated WT 0.76 
H1299 WT WT 1.86 Calu-6 Mutated WT 0.95 
HCC827 WT WT 2.00 H292 Mutated WT 0.95 
HCC1359 WT WT 2.00 H1975 WT WT 1.05 
PC-9 WT WT 2.40 HCC4011 WT WT 1.17 
H1819 WT WT 2.57 HCC78 WT WT 1.55 
HCC4006 WT WT 3.39 H2126 Mutated Mutated 0.49 
H820 WT WT 3.47 A549 Mutated Mutated 0.87 
H1792 Mutated WT 3.80 H460 Mutated Mutated 0.30 
H226 WT WT 3.89 H1355 Mutated Mutated 2.75 
H1650 Mutated WT 3.89 H1395 WT Mutated 4.17 
H2882 WT WT 4.07 H157 Mutated Mutated 0.16 
H2087 WT WT 4.47 H2073 WT Mutated 1.17 
H3255 WT WT 4.57 H1993 WT Mutated 1.29 
H1693 WT WT 5.13 H1666 WT Mutated 2.75 
H322 WT WT 6.03 HCC515 Mutated Mutated 4.37 
HCC2935 WT WT 6.46 H2122 Mutated Mutated 0.50 
HCC4017 Mutated WT 7.24 H23 Mutated Mutated 0.52 
HCC193 WT WT 7.94 H1437 WT Mutated 0.85 
Calu-1 Mutated WT 9.55 H2009 Mutated Mutated 1.07 
H596 WT WT 10.00 HCC44 Mutated Mutated 0.85 
H661 WT WT 16.98 HCC1195 WT Mutated 0.37 
H2887 Mutated WT 19.95 HCC366 Mutated Mutated 0.93 
H522 WT WT 32.36 HCC15 WT Mutated 0.95 
 
Table 1 IC50 to 8-Cl-Ado and  KRAS and LKB1 mutation status  of screened cell 
lines (in collaboration with Dr. John Minna at UTSW). 
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3.2 LKB1 regulates the cellular response to 8-Cl-Ado 
In order to study the role of LKB1 in the increased sensitivity toward 8-Cl-Ado 
treatment, two LKB1 deficient NSCLC cell lines were chosen: A549 and H460. 
These two cell lines were re-constituted with LKB1 by infecting with lentivirus 
carrying wild type LKB1 cDNA. The LKB1 expression was confirmed by western 
blot as shown in Figure 3.2 (A).  
Cells carrying either wild-type LKB1 or empty control vectors were treated with 
various doses of 8-Cl-Ado ranging from 0.1 µM to 20 µM for 72 hours. The 
comparison between the IC50 values shows that both A549-LKB1 and H460-
LKB1 cells are more resistance to 8-Cl-Ado than those with empty control 
vector (CTR), as shown in Figure 3.2 (B). In addition, the results were 
confirmed by using lenti-virus carrying shRNAs to stably knockdown LKB1 in 
KRAS mutant cell line, Calu6, as shown in Figure 3.2 (C). The proliferation 
assay was then repeated as mentioned previously on LKB1 isogenic Calu6 
cells, as shown in Figure 3.2 (D). The IC50 value revealed a consistent pattern 
that cells with LKB1 are more resistant to 8-Cl-Ado than cells without LKB1. 
These results show that LKB1 plays a role in protecting cells from 8-Cl-Ado.  
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Figure 3.2  LKB1 regulates the sensitivity to 8-Cl-Ado. (A) Western blot 
analysis for LKB1 re-constitution in H460 and A549 cells.  (B) Comparison of 
IC50 determined by proliferation assay to show cells with LKB1 re-
constitution became resistant to 8-Cl-Ado. 
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Figure 3.2 LKB1 regulates the sensitivity to 8-Cl-Ado. (B) Western blot 
analysis for LKB1 knockdown in Calu6 cells.   (D) Comparison of IC50 
determined by proliferation assay to show cells with LKB1 knockdown 
became sensitivity to 8-Cl-Ado. 
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3.3 LKB1 protects cell from 8-Cl-Ado induced ATP depletion 
AMPK has been shown to be the main cellular energy sensor and LKB1 has 
been shown to directly phosphorylate AMPK at the Thr172 site in response to 
energetic stress (31-33). A549 and H460 with LKB1 stable overexpression cells 
were then treated with 8-Cl-Ado for 24 hours. ACC is a direct downstream 
target of AMPK and its phosphorylation at Ser79 has been widely used as an 
indicator of AMPK activity (89). As shown in figure 3.3 (A) and (B), 8-Cl-Ado 
increased AMPK phosphorylation at Thr172 site in cells with LKB1 but not with 
empty vector control. Consistently, ACC phosphorylation was further increased 
by 8-Cl-Ado in A549-LKB1 and H460-LKB1 cells compared with the A549-CTR 
and H460-CTR cells.  This finding indicates that 8-Cl-Ado has the potential to 
activate AMPK in a LKB1-dependent manner.  
In addition, 8-Cl-Ado has been shown to be able to decrease endogenous ATP 
levels though targeting ATP synthase  (90). Given, the finding that 8-Cl-Ado 
activates AMPK signaling in a LKB1-dependent manner,  we hypothesized that 
8-Cl-Ado decreases the cellular ATP levels in NSCLC cells. However, LKB1 
may compensate the ATP reduction induced by 8-Cl-Ado by activating 
alternative pathways.  
ATP level in cells with 6 hour 8-Cl-Ado treatment was measured. As shown in 
Figure 3.3 (C), (D) and (E), 8-Cl-Ado decreased the ATP levels in all cell lines; 
however, LKB1-expressing cells had less 8-Cl-Ado induced ATP reduction 
compared to control cells. Treatment of cells with 8-Cl-Ado for 6 hours reduced 
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ATP levels in H661 cells with LKB1 knockdown to a greater extent than in cells 
with scramble control.  
The results were further confirmed by measuring 8-Cl-Ado induced ATP 
depletion in isogenic H460 and A549 cells by an LC-MS based ATP assay 
described previously (in collaboration with Dr. Varsha Gandhi) (76). As shown 
in Figure 3.3 (F) and (G), H460-CTR cells had a lower ATP baseline levels 
compared with H460-LKB1 cells. 8-Cl-Ado also decreased endogenous ATP 
levels in both H460-CTR and H460-LKB1 cells. However, H460-LKB1 cells had 
a lesser reduction than H460-CTR cells and their ATP levels rebounded to the 
baseline level after 24 hour treatment. Similar results were also found in 
isogenic A549 cells treated with 8-Cl-Ado. 8-Cl-Ado decreased endogenous 
ATP levels to a greater extent in A549-CTR than A549-LKB1 cells. These 
findings confirm the role of LKB1-AMPK signaling in maintaining the 
homeostasis of energy metabolism (74) and indicate the potential of targeting 
LKB1 deficient NSCLC through ATP depletion. 
It has been reported that AMPK can phosphorylate TSC2, which in turn inhibits 
mTOR signaling (42). Therefore, we attempted to study the effect of 8-Cl-Ado in 
the mTOR pathway. Phosphorylation of p70S6K was picked to be used as a 
marker for mTOR signaling. As shown in Figure 3.3 (A) and (B), western blot 
analysis demonstrates that 8-Cl-Ado causes de-phosphorylation of p70S6K in a 
LKB1 dependent manner.  This result suggests that 8-Cl-Ado has the potential 
to inhibit mTOR signaling through LKB1. However, its effect on LKB1 deficient 
cells is independent on mTOR signaling.  
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Overall, 8-Cl-Ado induces AMPK activation and mTOR inhibition in the 
presence of LKB1. As mentioned previously, energy stress induces AMPK 
phosphorylation by LKB1, and 8-Cl-Ado can decrease endogenous ATP. 
Therefore, I hypothesize that 8-Cl-Ado might target cellular energy metabolism, 
hence inhibit the growth of LKB1 deficient NSCLC. 
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Figure 3.3 8-Cl-Ado decreases cellular ATP level and induces AMPK 
activation in a LKB1 dependent manner.  (A) (B)  Western blot analysis for 
phos-ACC, phos-AMPK, phos-p70S6K and LKB1 showing that 8-Cl-Ado 
induced AMPK activation is LKB1 dependent. Lysates were collected from 
cells treated with 5µM 8-Cl-Ado for 24 hours 
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Figure 3.3 8-Cl-Ado decreases cellular ATP level and induces AMPK 
activation in a LKB1 dependent manner.  (C) (D) ATP level measurements of 
cells treated with 8-Cl-Ado at 0.5 µM, 1 µM, and 4 µM for 6 hours by 
luminescent method (ATPlite). Results were normalized with non-treated 
control. Statistical significances were determined by two way ANOVA 
multiple comparisons.  
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Figure 3.3 8-Cl-Ado decreases cellular ATP level and induces AMPK 
activation in a LKB1 dependent manner.  (E) ATP level measurements of 
cells treated with 8-Cl-Ado at at 0.5 µM, 1 µM, and 4 µM for 6 hours 
luminescent method (ATPlite). Result was normalized with non-treated 
control. Statistical significances were determined by two way ANOVA 
multiple comparisons.  
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Figure 3.3 8-Cl-Ado decreases cellular ATP level and induces AMPK 
activation in a LKB1 dependent manner.  (F) (G) ATP level measurements of 
cells treated with 8-Cl-Ado at 0.2 µM, 2 µM, and 20 µM for 6 and 24 hours by 
LC-MS method (in collaboration with Dr. Varsha Gandhi). Result was 
normalized with cells carry empty control vector without treatment. Statistical 
significances were determined by two way ANOVA multiple comparisons.  
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3.4 8-Cl-Ado induces oxidative stress in cells with LKB1 deficiency  
ROS is a by-product of mitochondrial respiration (54). Low to moderate ROS 
stimulates cell proliferation and differentiation (91). Excess ROS causes 
oxidative stress and subsequent cell death by damaging cellular components, 
such as DNA, proteins and lipids (54,72). Research has shown glucose 
starvation/2-DG treatment reduces intracellular ATP and induce ROS 
accumulation in lung cancer cells (74). Inside the cell, 8-Cl-Ado gets 
metabolized into 8-Cl-ADP and 8-Cl-ATP (92). ATP synthase is the last enzyme 
of the respiratory chain of oxidative phosphorylation. It catalyzes the synthesis 
of ATP from ADP.  It has been proposed that 8-Cl-ADP/8-Cl-ATP binds to ATP 
synthase in a similar mode as ATP/ADP. 8-Cl-ADP and 8-Cl-ATP together may 
be an inhibitor of ATP synthase (90).   In addition, inhibiting ATP synthase with 
the known inhibitor oligomycin could stall the electron transport chain and 
subsequently cause accumulation of electrons. Then, the excess electrons will 
convert oxygen to superoxide and to hydrogen peroxide. Based upon all the 
above facts, I wanted to investigate whether 8-Cl-Ado induced ATP reduction is 
associated with ROS accumulation.  
H1299 (LKB1 wild-type) and A549 (LKB1 mutant) cells were treated with 8-Cl-
Ado and 2-DG for 48 hours. As shown in Figure 3.4 (A) and (B), both 8-Cl-Ado 
and 2-DG treated H1299 cells did not show any accumulation of ROS. However, 
A549 cells showed an increase in ROS level for both treatments, with 8-Cl-Ado 
treatment causing the most increase in the accumulation of ROS. These results 
39 
 
suggest that LKB1 plays a role in protecting cells from 8-Cl-Ado induced ROS 
accumulation.   
To further investigate the role of LKB1 in 8-Cl-Ado induced ROS accumulation, 
isogenic A549, H661 and Calu6 cells were treated with 8-Cl-Ado for 48 hours.  
As expected, LKB1 reduces 8-Cl-Ado induced ROS accumulation in both A549-
LKB1 and Calu-6-SCR cells; however, A549-CTR and Calu-6 shLKB1 cells had 
greater accumulation of ROS, as shown in Figure 3.4 (C), (D) and (E). The 
NRF2 protein level in H460 and A549 isogenic pairs after 8-Cl-Ado treatment 
was also measured. As expected, 8-Cl-Ado increased NRF2 protein level in 
H460-CTR and A549-CTR cells, but not in H460-LKB1 and A549-LKB1 cells, as 
shown in Figure 3.4 (F). These findings suggest that 8-Cl-Ado induces ROS 
accumulation. However, LKB1 could protect cells from 8-Cl-Ado induced ROS. 
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Figure 3.4  LKB1 attenuates 8-Cl-Ado induced oxidative stress. (A) (B) 
FACS analysis of cellular ROS level of H1299 and A549 cells after 48 hour 5 
µM 8-Cl-Ado treatment. 
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Figure 3.4 LKB1 attenuates 8-Cl-Ado induced oxidative stress. (C) (D) (E) 
FACS analysis of cellular ROS level A549 cells with LKB1 re-constitution and 
Calu6 and H661 cells with LKB1 knockdown after 48 hour 5 µM 8-Cl-Ado 
treatment. The experiment was performed twice. The bar graph represents 
the percentage difference in mean value determined by FACS based upon 
measurement of 10,000 cells.  
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Figure 4. LKB1 attenuates 8-Cl-Ado induced oxidative stress. (F) Western 
blot analysis for LKB1 and NRF2. 
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3.5 LKB1 deficiency cells have enhanced the Warburg effect and impaired 
mitochondrial membrane potential 
In order to investigate the role of LKB1 in cellular metabolism, the seahorse 
assay was used to study the oxygen consumption rate (OCR) of isogenic A549 
and H661 cells at four different concentrations. According to manufacturer’s 
protocol, the OCR is a direct indicator of mitochondrial respiration. As show in 
Figure 3.5 (A) and (B), A549 cells with LKB1 expression showed an increase in 
OCR. However, H661 cells with LKB1 knockdown presented decreased OCR. 
This finding indicates a potential role of LKB1 in regulating cellular respiration. 
In addition, the Warburg effect suggests that cancer cells preferentially undergo 
aerobic glycolysis (45). This led to the hypothesis that LKB1 deficient cells are 
highly dependent on glycolysis for energy production. The glycolytic potential of 
isogenic A549 cells was then investigated using the seahorse assay. As 
expected, A549-LKB1 cells showed a decrease in the glycolysis compared to 
A549-CTR cells, as shown on Figure 3.5 (C). Overall, these findings suggest a 
novel role of LKB1 in regulating cellular metabolism by reversing the Warburg 
effect.  
The mitochondrial stress test was then performed on isogenic A549 cells. As 
shown in figure 3.5 (D), both A549-LKB1 and A549-CTR cells showed a 
reduction in OCR upon oligomycin treatment. However, A549-CTR cells failed 
to response to mitochondrial uncoupler FCCP, which collapses mitochondrial 
potential by depolarizing the mitochondrial member. FCCP causes a rapid 
consumption of energy and oxygen, but without generation of ATP (87).  
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This observation suggests that A549 cells with LKB1 deficiency may have a 
defective mitochondrial membrane potential. It further suggests that A549 CTR 
cells associated with high glycolysis may be due to the defective mitochondria.   
Finally, the mitochondrial membrane potential and mass in A549-CTR and 
A549 LKB1 cells was investigated. As is shown in Figure 3.5 (E) (F) and (G), 
A549-LKB1 cells had slightly higher membrane potential than A549 CTR cells. 
However, the mitochondrial mass of A549-CTR cells was much higher than in 
A549-LKB1 cells. The average mitochondrial membrane potential per unit of 
mitochondrial mass of A549-CTR cells was however much lower than in A549-
LKB1 cells. This finding confirms the results obtained earlier which showed that 
A549-CTR cells have a defective mitochondrial potential and subsequently 
depend more on glycolysis for energy production. 
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Figure 3.5 LKB1 deficiency shifts cells from aerobic respiration to anaerobic 
respiration. (A) (B) seahorse analysis of baseline OCR of A549 with LKB1 
re-constitution and H661 with LKB1 knockdown cells at three different cell 
concentrations. Data are presented as mean+/- SE. The experiment was 
performed once. Each cell line at each concentration had 4 replicates. The 
final OCR value is the average of 14 independent measurements of all 4 
replicates.  
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Figure 3.5 LKB1 deficiency shifts cells from aerobic respiration to anaerobic 
respiration. (C) Seahorse glycolytic analysis of A549 with LKB1 re-
constitution. The experiment was performed twice with 5 replicates for each 
cell line. (D) Seahorse mitochondrial stress test of A549 with LKB1 re-
constitution. The experiment was performed with 4 different concentrations 
of FCCP. Each cell line had 5 replicates. Data are presented as mean+/- SE. 
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Figure 3.5 LKb1 deficiency shifts cells from aerobic respiration to anaerobic 
respiration. (E) FACS analysis of mitochondrial potential of A549 cells with 
LKB1 re-constitution (F) FACS analysis of mitochondrial mass of A549 cells 
with LKB1 re-constitution. (G) Mitochondrial potential per unit mitochondrial 
mass of A549 cells with LKB1 re-constitution. The experiment was 
performed once. The bar graph represents the mean value determined by 
FACS based upon measurement of 10,000 cells. 
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CHAPTER 4: DISCUSSION 
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4.1 Overview 
Recent studies have shown a promising potential of targeting cell metabolism in 
LKB1 deficient NSCLC, but very little is known about the underlying mechanism 
involved. Since LKB1 is the third most mutated gene (after P53 and KRAS) in 
lung cancer  (4), this study specifically investigated the vulnerability of LKB1 
deficient NSCLC to metabolic disruption. It supports the ability of disrupting 
cellular energy metabolism and redox homeostasis to stall the growth of LKB1 
deficient NSCLC. To investigate the hypothesis, we screened a panel of 
NSCLC cell lines and identified 8-Cl-Ado selectively targets LKB1 deficient cells. 
The role of LKB1 in regulating cellular response to 8-Cl-Ado was further 
confirmed by stably re-constituting and knocking-down LKB1 in NSCLC cells. It 
has been previously shown that 8-Cl-Ado decreases endogenous ATP levels 
(76,90). In this study, we show that 8-Cl-Ado depletes endogenous ATP levels 
to a greater extent in LKB1 deficient cells compared to LKB1 expressing cells. 
We also demonstrate that 8-Cl-Ado causes the accumulation of reactive oxygen 
species in cells lacking LKB1 expression and again confirmed the protective 
role asserted by LKB1. Additionally, this study reveals that LKB1 regulates 
cellular metabolic reprogramming. It was supported by the observation that 
expression of LKB1 is associated with increased mitochondrial potential and 
oxygen consumption rate. Research has shown that defects in mitochondrial 
oxidative phosphorylation have been linked to Warburg effect (93). In addition 
to producing energy, the mitochondria also play an important role in regulating 
the redox state, cellular Ca2+ and apoptosis (55). Therefore, defective 
50 
 
mitochondrion may render the sensitivity of LKB1 deficient cells to energetic 
and oxidative stresses induced by 8-Cl-Ado.     
 
4.2 8-Cl-Ado and ATP depletion 
8-Cl-Ado has been shown to deplete ATP and was first reported in a study of 
mantle cell lymphoma (MCL) cell lines (94). In that study, it was evident that 8-
Cl-Ado gets metabolized to 8-Cl-ATP. The accumulation of 8-Cl-ATP was 
associated with a reduction in cellular ATP level. Later, studies have also 
shown that 8-Cl-ADP/8-Cl-ATP, metabolites of 8-Cl-Ado, could inhibit the ATP 
synthase on mitochondrial membrane by occupying the tight and loose binding 
sites of ATP synthase in a similar way as ADP/ATP (95). Oliogmycin used in 
the seahorse assay in this study is a known ATP synthase inhibitor. It causes 
immediate ATP synthase inhibition upon adding to the cell. However, 
substitution of Oliogmycin with 8-Cl-Ado on the seahorse assay did not show 
any acute inhibition of ATP synthase. This observation may be due to the fact 
that a longer incubation time is needed for 8-Cl-Ado to inhibit ATP synthase 
given that 8-Cl-Ado needs to be metabolized to 8-Cl-ATP and 8-Cl-ADP. It also 
suggests that 8-Cl-Ado may decrease cellular ATP level through alternative 
mechanisms. The data also show that LKB1 deficiency is associated with 
decreased oxygen consumption rate, increased extracellular acidification rate, 
and decreased mitochondrial membrane potential. It suggests that LKB1 
deficient cells are shifting towards glycolysis for energy production. Thus, it 
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raises a question of whether 8-Cl-Ado affects glycolysis and hence causes ATP 
depletion.  
 
4.3 LKB1 and metabolic reprograming 
This study revealed a novel role of LKB1 in reprograming the balance between 
oxidative phosphorylation and glycolysis in NSCLC. The “Warburg effect” states 
that cancer cells have increased glycolytic flux even in the presence of high 
oxygen tension (45,96,97). It has been shown that high glycolysis could offer 
cancer cells with several survival advantages. First, high glycolysis in cancer 
cells could enable them to survive under condition with limited oxygen supply. 
Second, production of lactic acid could make an acidic environment that favors 
cancer cell invasion. Third, NADPH plays an anti-oxidant role in protecting cells 
from chemotherapeutic agents (97). Mice studies have shown that KRASG12D 
driven mice with LKB1 conditionally knockout in lung are resistant to 
chemotherapy and chemotherapy plus MEK inhibitor (20). In addition, lung 
tumors from those mice displayed an increased distant metastasis and 
expression of angiogenic factors (13,14). However, the role of LKB1 in 
increased resistance and metastasis has not yet been elucidated. Given the 
advantages of high glycolysis to tumor cells, the observation of LKB1 deficiency 
induced high glycolysis in this study would potentially fill this gap of knowledge.    
AMPK directly regulates the autophagy kinase ULK1 to regulate mitophagy and 
survival under conditions of cellular stress. In response to energy stress, AMPK 
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can activate mitophagy through activating ULK1(100). Mitophagy then can 
remove damaged or dysfunctional mitochondria to prevent cell death. In this 
case, the difference in mitochondrial mass may be due to the failure of 
mitophagy activation in LKB1 deficient cells. Alternatively, cells may increase 
mitochondrial mass to compensate for low mitochondrial activity. Thus, further 
studies are needed to investigate this mechanism.  
 
 
4.4 8-Cl-Ado and oxidative stress 
ROS is a byproduct of oxidative phosphorylation in proliferating cells. Electrons 
from NAPH and succinate of TCA cycle pass through the electron transport 
chain and reduce oxygen to water. However, excess electrons at complex I and 
complex III contribute to a partial reduction of oxygen to superoxide anions. 
Immediately, these superoxide anions get dismutated to hydrogen peroxide by 
dismutases. For the first time, this study demonstrates that 8-Cl-Ado could 
cause ROS accumulation, especially in those cells without LKB1 expression. 
Inhibition of ATP synthase by oligomycin could stall the electron transport chain 
and reduce the electron carriers in complexes I and III and CoQ, which causes 
an accumulation of free electrons. Those excess electrons can then be 
converted to superoxide and hydrogen peroxide (55). As mentioned above, 8-
Cl-Ado could inhibit ATP synthase, which is the last complex on the electron 
transport chain. Therefore, 8-Cl-Ado may function in a similar way as 
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oligomycin by raising the mitochondrial inner membrane polarization and 
subsequently resulting in an accumulation of electrons.  
 
4.5 LKB1 and oxidative stress  
Recently a study has shown that LKB1 regulates fatty acid oxidation through 
AMPK-ACC axis and thereby protecting cells from energetic and oxidative 
stress (18). Fatty acid are an alternative energy source in addition to glucose 
and glutamine. Proliferating cells require sustained supply of fatty acids for their 
cellular membrane synthesis. The synthesis of fatty acids is an anabolic 
process, which consumes ATP. On the other hand, fatty acid oxidation is a 
catabolic process that fuels the TCA cycle and electron transport chain with 
acetyl CoA, NADPH and FADH2. In addition, acetyl CoA from fatty acid 
oxidation could enter a series reaction to give rise to cytosolic NADPH, which is 
a key anti-oxidant molecule in cells.   
Under energetic stress, LKB1 will phosphorylate AMPK in response to the 
stress. Phosphorylated AMPK will then inhibit ACC through phosphorylation. 
Inhibition of ACC could stop the synthesis of fatty acid (98), which conserves 
the ATP. At the same time, inhibition of ACC turns on the fatty acid oxidation 
process. As mentioned above, it produces acetyl CoA, NADPH and FADH2 for 
the TCA cycle and electron transport chain thus generating more ATP. It also 
gives rise to NADPH, which detoxifies ROS, and hence protects the cell from 
both energetic and oxidative stress. In this study, we have shown that 8-Cl-Ado 
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could induce ACC phosphorylation in a LKB1 dependent manner. Also, LKB1 
could attenuate 8-Cl-Ado induced ATP reduction and ROS accumulation. Given 
the role of fatty acid oxidation and its connection with LKB1-AMPK signaling, 
dysregulation of fatty acid synthesis and oxidation may render the sensitivity of 
LKB1 deficient cells to 8-Cl-Ado. Overall, this study revealed 8-Cl-Ado as a 
potential drug that could target LKB1 deficient NSCLC. It also suggests that 
disrupted metabolic and redox controls in LKB1 deficient cells can be a 
potential vulnerability for targeting.   
 
4.6 8-Cl-Ado and cell death 
Cell cycle anaylsis, as shown on Figure 4.1, did not show any change in cell 
cycle due to LKB1. Calu6 cells with LKB1 knockdown displayed an increase in 
sub G1 phase after 8-Cl-Ado treatment. Sub G1 phase includes dead cells with 
low DNA content. This result indictates that 8-Cl-Ado may induce cell death in 
LKB1 deficient cells. However, similar results are not seen on H441 cells with 
LKB1 knockdown. Therefore, further studies are needed to investigate 8-Cl-Ado 
induced cell death in LKB1 deficient cells. 
The initial cell line screening was performed using an MTT assay (in 
collaboration with Dr. John Minna at UTSW).  The MTT assay is based upon 
cellular NADH, which is considered as an indicator of cellular viability. CellTiter-
Glo assay is an ATP based assay. It is believed that the the amount of ATP is 
proportional to the amount of live cells. Given by the role of LKB1 and 8-Cl-Ado 
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in cell metabolism, both methods used in this study may not be ideal 
approaches. However, the acute effect of 8-Cl-Ado is not expected to last 
beyond 72 hours. Thus, the end point differences determined by these two 
methods are believed to be mainly dominated by the actual differences in cell 
number. Future approaches, such as counting cell number by DAPI staining 
and DNA content based assays should be deployed.  
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Figure 4.1 Cell cycle analysis. Cell cycle analysis by FACS on H441 and 
Calu6 cells with LKB1 knockdown after 72 hours 8-Cl-Ado treatment.  
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4.7 Future direction 
Although this work has demonstrated that LKB1 deficient NSCLC cells are 
associated with a metabolic alternation and a potential sensitivity to energy 
stress induced by 8-Cl-Ado, there still remains some unanswered questions.  It 
is important to investigate the mechanism of how LKB1 regulates the switch 
between glycolysis and mitochondrial respiration. Global metabolomics 
screening could provide information on the metabolites affected by LKB1. This 
metabolic alteration may bring survival advantages to LKB1 deficient NSCLC, 
but it also can be a potential target. Given the reported findings that NSCLC 
with Kras mutation more depends on glutamine for energy production but not 
glycolysis (99), it is also interesting to study the contribution of increased 
glycolysis to the tumorigenesis of LKB1 deficient NSCLC. Furthermore, it would 
be critical to investigate the mechanism of action of 8-Cl-Ado in ATP depletion 
and ROS accumulation. It is necessary to test if 8-Cl-Ado targets ATP synthase 
to decrease ATP level in LKB1 deficient NSCLC cells, or it may actually target 
glycolysis. ROS accumulation may be due to either excess production or 
defective anti-oxidant response. It is important to determine if 8-Cl-Ado could 
affect any of these two mechanisms.  
It would also be important to determine the pathways that LKB1 regulated that 
contribute to the protection of cells from 8-Cl-Ado. A gene expression analysis 
could provide a complete understanding of pathways that regulated by LKB1 
and affected by 8-Cl-Ado. The result can also be correlated with metabolomics 
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analysis, which will give a comprehensive understanding of how LKB1 regulates 
cellular metabolism and the mechanism of action of 8-Cl-Ado. 
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